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In considering the state of epidemiologic research, these are the ''best'' and the ''worst'' of times-the ''best'' from the perspective of scientific opportunities and the ''worst'' from the perspective of funding. In this commentary, the authors address this time of funding austerity from the points of view of individual researchers and research institutions. For researchers, the new tools of ''-omics,'' large databases, communication by means of the World Wide Web, and global access offer ever-expanding scientific opportunities. The authors comment on research directions for which there is an enhanced likelihood of funding success: clinical and translational research, outcomes and effectiveness research, and global health research. The authors emphasize the need to be innovative and not bound by the conventional. For institutions, the authors suggest attention to innovation and impact, social networking, and finding the ''right size'' for training programs. Academic institutions also need to invest, supporting researchers and their ideas. Epidemiologists need to be true to their mission and prove that they can use innovation to advance health and welfare in a measurable way. Doing so will ensure that over the long term, epidemiologic research will remain a cornerstone for advancing population health. epidemiology; funding; innovation; research Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; NIH, National Institutes of Health.
''It was the best of times, it was the worst of times. It was the age of wisdom, it was the age of foolishness. It was the epoch of belief, it was the epoch of incredulity. It was the season of Light, it was the season of Darkness. It was the spring of hope, it was the winter of despair . . .'' Charles Dickens, A Tale of Two Cities
The opening lines of A Tale of Two Cities (1) seem an eerily accurate mirror for the current moment in epidemiology. ''The best of times'' reflects the continued centrality that epidemiology claims as the basic science of public health and medicine. Enlarged opportunities arise from applying new tools and technologies to the exploration of the mechanistic basis of disease and its translation into ''personalized medicine'' (2). The Internet provides vastly expanded prospects for collaboration and for immediately accessing informative data. Our national focus on globalization and its consequences allows epidemiologists to direct their insights to the most vulnerable of the world's populations.
However, ''the worst of times'' are also upon us with respect to federal funding. The research funding ''feast'' that began in the 1990s has become a relative ''famine'' of uncertain severity. The budget for the National Institutes of Health (NIH) for the 2012 fiscal year will put it (in terms of purchasing power) back where it was in 2000, thereby continuing to ''unwind'' the historic (1998) (1999) (2000) (2001) (2002) (2003) budget doubling of the past 2 decades (3). The NIH, which funds 84% of all federal biomedical research, will fund about 1,000 fewer grants in 2012 than it did in 2003. Moreover, this period of austerity comes after a ''bubble'' of funding and training that created a surfeit of research capacity and has made the competition for declining resources ever fiercer. Another facet of ''the worst of times'' is the attack on epidemiology by powerful industrial stakeholders, who, as documented in recent books such as Merchants of Doubt (4) and Doubt Is Their Product (5), have cast epidemiology as a ''soft'' rather than a ''sound'' science and hence of limited value for decision-making. Epidemiologists need to be aware of such strategies and to counter them in order to avoid marginalization.
The best-and-worst metaphor also reminds us that 2 people sitting in different positions with respect to a mirror can see their reflections differently. Below we will look at the funding crisis in epidemiology from the perspective of the individual scientist and from that of the institution/society.
For the epidemiologic scientist, the key question is, ''How do I respond to the current reduction in pay lines and funding in order to maintain research support?'' As a starting point, a ''good grant'' is still requisite, with novelty and cutting-edge inquiry being of ever-greater import. Proving that research is ''innovative'' demands far more than simply periodically inserting the word into the text of a grant application. Admittedly, replication is a cornerstone of scientific research, but circular churning of research with a larger sample size, a promise of less misclassification, and a more informative population than the last study almost inevitably fails (6) .
Instead, success is likely to be embedded in the very opportunities that make this the best of times: new ''-omics'' tools (genomics, proteomics, and metabolomics, for example); greater access to existing large databases, consortial pooled resources, and cohorts; communication via the World Wide Web, with more diverse interdisciplinary teams; and access to global residents and natural experiments. More specifically:
Riding the wave of new approaches is always ''sexy,'' but the research question must be solidly grounded in an interesting hypothesis about how biology acts in disease pathogenesis, natural history, or treatment. The National Cancer Institute's Provocative Questions Project (http:// provocativequestions.nci.nih.gov/) offers one resource and example for relevant and significant research questions. While comparative effectiveness research and clinical and translational research are not ''new,'' they are receiving increased attention and funding. Health-care reform has elevated the priority of health services research. Clinical Translational Science Awards provide expanded infrastructure for clinical/translational research. These disciplines use tools that greatly overlap with ours and should be considered ripe prospects for epidemiologists. Building on existing resources is increasingly attractive at a time when it is difficult to obtain support for establishing entirely new research populations. The new culture of data-sharing and open access has made accessible a wide array of data from government agencies, NIH-supported researchers, and health-care systems, among others (7). Many health-care institutions are seeking to establish patient cohorts by joining medical record and questionnaire data with biobanks and outcome tracking. Contemporary epidemiology inherently calls for multidisciplinary perspectives, and the NIH increasingly calls for cross-cutting designs. The broader the range of collaborators, the more novel the research possibilitiesfor example, teaming with partners from engineering, sociology, economics, or communications. Epidemiologic evidence is needed to advance public health in many low-and middle-income countries. While funding has been abundant for research on malaria, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis, and some other infectious diseases, there has been far less support available for other critical research domains, such as noncommunicable diseases, mental health, the environment, and traffic safety. These are big problems, and funds are starting to become available for research on select issues. The problem of noncommunicable diseases was highlighted at a recent high-level United Nations meeting, only the second directed at health and disease-the first being the 2000 meeting on HIV/AIDS (8).
For institutions and society, the key question is: How does epidemiology maximize its core mission during a time of resource constriction? Here, the most salient quote may be from Ernest Rutherford, iconic experimentalist and father of nuclear physics: ''We haven't the money, so we've got to think'' (9) .
What is our core mission? Surely we can find its expression within the mission statement of our largest federal funder, the NIH: ''To seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability'' (http://www.nih.gov/about/mission. htm). That mission (and ours) combines several frames: 1) knowledge acquisition and progress 2) made by seekers (scholars) 3) to be used to enhance health and welfare. Said another way, our mission is new progress with a use, a process that is the very definition of innovation. New insights followed by new applications lead to the knowledge that fuels advances in welfare and health. These advances will not come without innovation. The question then becomes: How does innovation align with the reality that science is big business (requiring adequate revenues to offsets costs and maintain a profit margin) facing declining revenues? Before confronting this dilemma, let us practice a short-lived disregard for money and instead focus on how our mission-driven aspirations impact innovation.
Knowledge acquisition and progress imply a forwarddirected quest for the truths that underlie the workings of nature. Anything that detracts from headlong advancement is suspect, yet innovation and creativity are inherently nonlinear (10) . In fact, some of the best ideas are surprising and even playful. One of the most creative forms of expression is the joke, but of course science is no joking matter. And yet, if we had circumscribed wide-ranging curiosity, a roving eye for observation, and a willingness to move beyond the acceptable, many important insights (the discoveries of penicillin and of Helicobacter pylori, the cause of pellagra, and the ''back to sleep'' intervention for sudden infant death syndrome, to name a few) would have been missed. In other words, the current funding situation demands being bold and not sticking to the linear ''tried and true.'' The drive to improve health and welfare is exactly what distinguishes public health and medical science from the unencumbered mischievousness that can be a basis for business or the arts. When life and death are at stake, science appropriately imposes restrictions and regulations that protect human subjects and limit population exposures. Nonetheless, fear of change and novelty is one of the most chilling influences on innovation; too much constraint and conformity limit an element critical to creativity: risk-taking. Increasingly, usefulness is not a metric but the metric for supporting a line of research. Applicability (clinical/public health relevance), accountability (making a measurable difference), and entrepreneurship emphasize product rather than process, output rather than discovery; but focusing laser-like attention on usefulness risks missing many if not most of the breakthroughs that occur in science. These are often serendipitous-found by ''prepared minds'' while looking for something else-or they are off-target, not initially thought to be useful (e.g., using antiretroviral agents not for the treatment of HIV but for prevention). Large gains in public health are more likely to come from new approaches and paying keen attention than from marginal advances in what we are already doing. A community of scholars can both benefit and hinder innovation. Science is notably hierarchical, with senior scientists controlling scientific reviews and thus resources; dominating advisory committees and thus decisionmaking; and leading professional organizations and thus advocacy. This structure ensures the entrenchment of habitual views (think hormone therapy and cardiovascular disease). On the other hand, there is ample evidence for the old adage, ''Two heads are better than one.'' The Web may provide a mechanism for harnessing the power of groups while limiting the confinement of ''groupthink.'' New researchers need new mechanisms for encouragement.
We acknowledge that implying that the frames which underlie our mission may threaten innovation is like debunking Mom and apple pie. Nonetheless, there are unintended consequences of staying with the status quo. Moreover, this discussion contextualizes how restricted funding impacts innovation. We believe that all of the above concerns become amplified during times of resource constraint and uncertainty. Fears rise, risk-taking is diminished, feasibility becomes paramount, and capitalization through usefulness is immensely attractive.
What can our institutions do? First, we can recall that the dedicated, starry-eyed do-gooders populating the student and junior faculty ranks of epidemiology come to the field not for the money but for the intangibles: the ability to study what fascinates them and to learn something that makes them, for an instant, ''the only person on earth who knows this.'' Decades of creativity research suggest that great minds are enticed by intrinsic, not extrinsic, motivation (10) . Given that money is not the primary motivator, can academic and research institutions take a step away from business and become less about the money? Could we use metrics other than extramural funding to compare institutions and to value investigators? Could we recognize the epidemiologist who did the most with the least rather than the one with the biggest grant budget? Can we find tools to measure what difference research and researchers have actually made? Second, we can invest, truly invest, in innovation. This means identifying wild ideas that are ''on the edge'' and allowing their creators the gift of time and perhaps a little pilot funding to pursue them to failure or success. Academic institutions need to think about research not solely as a revenue stream. We must invest in ideas even if it is at the expense of support for administration and new buildings.
Third, we can recognize that innovation has a high rate of failure (just ask a venture capitalist). Thus, to allow for more innovation, we must fail smarter. This means allowing smaller grants that support prototype projects but still motivate faculty by supporting investigator time.
Fourth, we must catapult into the 21st century of social networking by using the Web as a tool that may be as powerful as ''-omics'' to solve tricky public health problems. For example, using a website called the Polymath Project (http://projectpolymath.org/), mathematicians found a new proof for a theorem that had previously defied solutions; competing to create the best algorithm, computer scientists engaging over the Web in the MATLAB online programming competition one-up each other in improving their solutions over the 10 days of the contest by an average of 1,000-fold (the rules encourage stealing posted algorithms, tweaking them, and then reposting them for a better score) (11, 12) . A social networking site called ResearchGate (http:// www.researchgate.net/)) connects 1.3 million scientists (and growing), hosts discussions, and allows everyone to share preprints. Whether it is across the globe or within our own institutions, we need to better network researchers into multidisciplinary teams that will address problems in a meaningful way.
Fifth, we should reflect on questions of training and manpower in epidemiology. Are our training programs relevant to the changing methods in our field? Are we providing students with a thought-provoking toolbox for contextualizing the massive content of information they will encounter? Are we teaching them to think systematically and innovatively in a way that will remain relevant? We must also consider the number of epidemiologists we are training. Schools of public health and epidemiologic training programs have grown rapidly. But if the ''new normal'' is flat NIH funding, should we continue to pump out graduatelevel epidemiologists? Moreover, are our training programs the best venues for building capacity in low-and middleincome countries? Perhaps now is a time for ''right-sizing'' of research capacity in epidemiology, an undiscussed topic.
Epidemiologists, as individuals and through professional organizations, can be proactive in advocating for needed funding; but as Bruce Alberts, editor of Science, points out, the usual call for more resources in these modern times will likely fall on deaf ears (13) . Instead, we need to be true to our mission and prove that we can use innovation to advance health and welfare in a measurable way, in a way that is not ''just about the money.'' Doing so will ensure that over the long term, epidemiologic research will remain a cornerstone for advancing population health-and that ultimately, ''the worst of times'' will come to an end.
